| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
HCWB's 1-for-6 reverse split on June 30 is structurally cleaner than typical toxic reverse splits: the stock organically earned compliance above $1.00 before the split, will shrink to 1.59M outstanding shares creating a tight low-float structure, and has synchronized catalysts (compliance notification, clinical data readouts for HCW9302) positioned to drive momentum.
HCWB will reach the 20-day closing above $1 threshold required for Nasdaq compliance today (June 12), triggering a formal regained compliance announcement within 1-2 weeks, which should provide a positive catalyst for the stock.
Three insiders (CEO, director, and CFO) made simultaneous purchases totaling over 306,000 shares, suggesting management confidence in the company's near-term prospects. The author expects a positive price reaction.
End of results.